CMPS

COMPASS Pathways plc is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, trading on Nasdaq under the symbol CMPS. The company has developed COMP360, an investigational synthesized formulation of psilocybin, and is researching its effectiveness for serious mental health disorders including treatment-resistant depression, post-traumatic stress disorder, and anorexia nervosa. COMPASS successfully achieved the primary endpoint in its first Phase 3 trial (COMP005) evaluating COMP360 psilocybin for treatment-resistant depression, marking the first Phase 3 efficacy data reported for an investigational synthetic psilocybin and the first classic psychedelic compound to reach this milestone. COMP360 has received Breakthrough Therapy designation from the U.S. FDA and Innovative Licensing and Access Pathway (ILAP) designation in the UK, with psilocybin therapy sessions typically lasting 6 to 8 hours with a therapist present throughout.